

Please type a number inside this box → +

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	09/529,925
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	Julv 30. 2000
		First Named Inventor	Elias Georges
		Group Art Unit	1653
		Examiner Name	H. Robinson
		Attorney Docket Number	641050.90013 (12705.4)
Sheet	2	of	10

RECEIVED
OCT 24 2002
TECH CENTER 1690/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AR		Pepinsky, R. Blake, et al., "Epidermal growth factor-dependent phosphorylation of lipocortin". Nature 321:81-84 (1986).	/
		Higgins, Christopher F. "ABC Transporters: From Microorganisms to Man". Annu. Rev. Cell Biol. 8:67-113 (1992).	/
		Lowe, Scott W. "p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents". Cell 74:957-967 (1993).	/
		Pollard, Harvey B., et al. "Ca ²⁺ -activated synexin forms highly selective, voltage-gated Ca ²⁺ channels in phosphatidylserine bilayer membranes". Proc. Natl. Acad. Sci. USA 85:2974-2978 (1968).	/
AR		Wang, Wei, et al., "Role of the Amino-Terminal Domain in Regulating Interactions of Annexin I with membranes: Effects of Amino-Terminal Truncation and Mutagenesis of the Phosphorylation Sites". Biochemistry 33:275-282 (1994).	/
		Bagetto, L.G., "Non P-glycoprotein novel proteins involved in human cancer multidrug resistance". Bull Cancer 84(4):385-390 (1997).	/
		Miller, Paul S., et al., "Oligonucleotide Inhibitors of Gene Expression in Living Cells: New Opportunities in Drug Design". Annual Reports in Medicinal Chemistry 23:295-304.	/
		Walker, J. Terrance, et al., "Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system". Proc. Natl. Acad. Sci. USA 89:392-396 (1992).	/
		Kwoh, D.Y., et al., "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format". Proc. Natl. Acad. Sci. USA 86:1173-1177 (1989).	/
		Scheffer, Georges, et al., "The drug resistance-related protein LRP is the human major vault protein". Nature Medicine 1(6):578-582 (1995).	/
		Sognier, Marguerie A., et al., "Sequestration of doxorubicin in vesicles in a multidrug-resistant cell line (LZ-100)". Biochemical Pharmacology 48(2):391-401 (1994).	/

Examiner Signature		Date Considered	1/14/03
---------------------------	--	------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

5316220_1.PDF



Please type and sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/529,925		
		Filing Date	Julv 30. 2000		
		First Named Inventor	Elias Georges		
		Group Art Unit	1653		
		Examiner Name	H. Robinson		
Sheet	3	of	10	Attorney Docket Number	641050.90013 (12705.4)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Cole, Susan P.C., et al., "Multidrug resistance associated with overexpression of MRP". Cancer Treat. Res. 87:39-62 (1996).	✓
		Nooter, K., et al., "Clinical relevance of P-Glycoprotein expression in haematological malignancies". Leukemia Research 18(4):233-243 (1994).	✓
		Flier, Jeffrey S., et al., "Multiple-drug resistance in human cancer". The New England Journal of Medicine 316(22):1388-1393 (1987).	✓
		Linn, Sabine C., et al., "Clinical and Pharmacologic Study of Multidrug Resistance Reversal with Vinblastine and Bepridil". Journal of Clinical Oncology 12(4):812-819 (1994).	✓
		Lazardi, Paul M., et al., "Exponential amplification of recombinant-RNA hybridization probes". Biotechnology 6:1197-1202 (1988).	✓
		Hijazi, Yasmine M., et al., "Immunohistochemical Detection of P-glycoprotein in Ewing's Sarcoma and peripheral Primitive Neuroectodermal Tumors before and after Chemotherapy". Anatomic Pathology 102(1):61-67 (1994).	✓
		Klohs, Wayne D., et al., "The Effect of Lysosomotropic Agents and Secretory Inhibitors on Anthracycline Retention and Activity in Multiple Drug-Resistant Cells". Molecular Pharmacology 34:180-185 (1988).	✓
		Lonn, Ulf, et al., "Intratumoral heterogeneity for amplified genes in human breast carcinoma". Int. J. Cancer 58:40-45 (1994).	✓
		Bradley, Grace et al., "Sex-Dependent and Independent Expression of the P-Glycoprotein Isoforms in Chinese Hamster". Journal of Cellular Physiology 145:398-408 (1990).	✓
		Henson, John W., et al., "P-glycoprotein expression in brain tumors". Journal of Neuro-Oncology 14:37-43 (1992).	✓
		Belloni, Paula N., et al., "Microvascular endothelial cell heterogeneity: Interactions with leukocytes and tumor cells". Cancer and Metastasis Reviews 8:353-389 (1989/1990).	✓

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside the box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 10

Complete if Known

Application Number 09/529,925
Filing Date July 30, 2000
First Named Inventor Elias Georges
Group Art Unit 1653
Examiner Name H. Robinson
Attorney Docket Number 641050.90013 (12705.4)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AK		Cordon-Cardo, C., et al., "Expression of the Multidrug Resistance Gene Product (P-Glycoprotein) in Human Normal and Tumor Tissues ¹ ". The Journal of Histochemistry and Cytochemistry 38(9):1277-1287 (1990).	✓
		Georges, Elias, et al., "Modulation of ATP and Drug Binding by Monoclonal Antibodies Against P-Glycoprotein". Journal of Cellular Physiology 148:479-484 (1991).	✓
		Charpin, C., et al., "Quantitative Immuno-cytochemical Assays of P-glycoprotein in Breast Carcinomas: Correlation to Messenger RNA Expression and to Immunohistochemical Prognostic Indicators". Journal of the National Cancer Institute 86(20):1539-1546 (1994).	✓
		Cole, Susan P.C., et al., "Pharmacological Characterization of Multidrug Resistant MRP-transfected Human Tumor Cells ¹ ". Cancer Research 54:5902-5910 (1994).	✓
		Creutz, Carl E., et al., "Effects of the expression of mammalian annexins in yeast secretory mutants". Journal of Cell Science 103:1177-1192 (1992).	✓
		Raynal, Patrick, et al. "Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins". Biochimica et Biophysica Acta 1197:63-93 (1994).	✓
		Lowe, Scott W., et al., "p53 Status and the Efficacy of Cancer Therapy In Vivo". Science 266:807-810 (1994).	✓
		Doige, Carl A., et al., "Transport properties of P-glycoprotein in plasma membrane vesicles from multidrug-resistant Chinese hamster ovary cells". Biochimica et Biophysica Acta 1109:161-171 (1992).	✓
		Mirski, Shelagh E.L., et al., "Multidrug Resistance in a Human Small Cell Lung Cancer Cell Line Selected in Adriamycin ¹ ". Cancer Research 47:2594-2598 (1987).	✓
		Walker, G. Terrance, et al., "Strand displacement amplification--an isothermal, in vitro DNA amplification technique". Nucleic Acids Research 20(7):1691-1696 (1992).	✓
		Thiebaut, Franz, et al., "Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues". Proc. Natl. Acad. Sci. USA 84:7735-7738 (1987).	✓

Examiner Signature

H. Robinson

Date


Considered

8/14/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type and sign inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/529,925
		Filing Date	July 30, 2000
		First Named Inventor	Elias Georges
		Group Art Unit	1653
		Examiner Name	H. Robinson
		Attorney Docket Number	641050.90013 (12705.4)
Sheet	5	of	10

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Wallner, Barbara P., et al., "Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity". Nature 320:77-81 (1986).	✓
		Gottesman, Michael M., et al., "Biochemistry of Multidrug resistance mediated by the multidrug transporter1". Annu. Rev. Biochem. 62:385-427 (1993).	✓
		Laemmli, U.K., "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4". Nature 227:680-685 (1970).	✓
		Shapiro, Adam B., et al., "ATPase Activity of Purified and Reconstituted P-glycoprotein from Chinese Hamster Ovary Cells". The Journal of Biological Chemistry 269(5):3745-3754 (1994).	✓
		Schinkei, Alfred H., et al., "Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins". Proc. Natl. Acad. Sci. USA 94:4028-4033 (1997).	✓
		Lin, Hsin Chieh, et al., "Annexin VI is Required for Budding of Clathrin-coated Pits". Cell 70:283-291 (1992).	✓
		Thorgeirsson, S.S., et al., "Expression of the Multidrug-resistant Gene in Hepatocarcinogenesis and Regenerating Rat Liver2". Science 236:1120-1122 (1987).	✓
		Varticovski, Luyba, et al., "Location of Sites in Human Lipocortin I that are Phosphorylated by Protein Tyrosine Kinases and Protein Kinases A and C". Biochemistry 27:3682-3690 (1988).	✓
		Wang, Wei, et al., "Regulation of the Chromaffin Granule Aggregating Activity of Annexin I by Phosphorylation". Biochemistry 31:9934-9939 (1992).	✓
		Batist, Gerald, et al., "Overexpression of a Novel Anionic Glutathione Transferase in Multidrug-resistant Human Breast Cancer Cells". The Journal of Biological Chemistry 261(33):15544-15549 (1986).	✓
		Tew, Kenneth D., "Glutathione-associated Enzymes in Anticancer Drug Resistance1". Cancer Research 54:4313-4320 (1994).	✓

Examiner Signature		Date Considered	1/14/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/529,925
		Filing Date	Julv 30, 2000
		First Named Inventor	Elias Georges
		Group Art Unit	1653
		Examiner Name	H. Robinson
		Attorney Docket Number	641050.90013 (12705.4)
Sheet	6	of	10


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
HJR		Chan, Helen S.L., et al., "P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for Neuroblastoma". The New England Journal of Medicine pp. 1608-1614 (1991).	✓
		Zaman, G.J.R., et al., "The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump". Proc. Natl. Acad. Sci. USA 91:8822-8826 (1994).	✓
		Pouliot, Jean-Francois, et al., "Reversal of P-Glycoprotein-Associated Multidrug Resistance by Ivermectin". Biochemical Pharmacology 53:17-25 (1997).	✓
		Schinkel, A.H., et al., "Disruption of the Mouse mdr1a P-Glycoprotein Gene Leads to a Deficiency in the Blood-Brain Barrier and to Increased Sensitivity to Drugs". Cell 77:491-502 (1994).	✓
		Fojo, A.T., et al., "Expression of a multidrug-resistance gene in human tumors and tissues". Proc. Natl. Acad. Sci. USA 84:265-269 (1987).	✓
		Abbaszadegan, Mohammad R., et al., "Evidence for Cytoplasmic P-Glycoprotein Location Associated with Increased Multidrug Resistance to Chemosensitizers". Cancer Research 56:5435-5441 (1996).	✓
		Ferguson, Peter J., "Critical Issues Relating to Clinical Drug Resistance". The Cancer Bulletin 41(1):7-13 (1989).	✓
		Beck, William T., "The cell biology of multiple drug resistance". Biochemical Pharmacology 36(18):2879-2887 (1987).	✓
		Endicott, Jane A., "The Biochemistry of P-Glycoprotein-mediated Multidrug Resistance ¹ ". Annu. Rev. Biochem. 58:137-171 (1989).	✓
		Gros, Philippe, et al., "Isolation and expression of a complementary DNA that confers multidrug resistance". Nature 323(6090):728-731 (1986).	✓
	Bradley, Grace, et al., "P-Glycoprotein Expression in Multidrug-resistant Human Ovarian Carcinoma Cell Lines ¹ ". Cancer Research 49:2790-2796 (1989).	✓	

Examiner Signature		Date Considered	1/14/03
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) in this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/529,925
		Filing Date	Julv 30. 2000
		First Named Inventor	Elias Georges
		Group Art Unit	1653
		Examiner Name	H. Robinson
		Attorney Docket Number	641050.90013 (12705.4)
Sheet	7	of	10

RECEIVED
OCT 24 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ck		Malek, Larry, et al., "Nucleic Acid Sequence-based Amplification (NASBATM)". Methods in Molecular Biology 28:253-261 (1994).	✓
		Raynal, Patrick, et al., "Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins". Biochimica et Biophysica Acta 1197:63-93 (1994).	✓
		Scharf, Stephen J., "Cloning with PCR". Academic Press Inc. pp. 84-91 (1990).	✓
		McGrath, Tim, et al., "Adriamycin Resistance in HL60 Cells in the Absence of Detectable P-glycoprotein". Biochemical and Biophysical Research Communications 145(3):1171-1176 (1987).	✓
		Froelich-Ammon, Stacie J., et al., "Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism". The Journal of Biological Chemistry 270(87):21429-21432 (1995).	✓
		Weiss, Rick, "Hot Prospect for New Gene Amplifier". Science 254:1292-1293 (1991).	✓
		Creutz, Carl E., et al., "Identification of Chromaffin Granule-binding Proteins". The Journal of Biological Chemistry 262(4):1860-1868 (1987).	✓
		Wang, Ying, et al., "Overexpression of a 400-kDa Protein in Human Multidrug Resistant Cells". Biochemical and Biophysical Research Communizations 236:483-488 (1997).	✓
		Baker, Raymond M., et al., "Detection of P-Glycoprotein in Human Tumors". Cancer Investigation 8(2):255-256 (1990).	✓
		Bradley, Grace, et al., "Mechanism of multidrug resistance". Biochimica et Biophysica Acta 948:87-128 (1988).	✓
		Abe, Yoshiyuki, et al., "Expression of the Multidrug Resistance Gene (MDRI) in Non-small Cell Lung Cancer". Jpn. J. Cancer Res. 85:536-541 (1994).	✓

Examiner Signature		Date Considered	1/14/03
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type or print your signature inside this box → +

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 8 of 10		Complete if Known	
		Application Number	09/529,925
		Filing Date	Julv 30. 2000
		First Named Inventor	Elias Georges
		Group Art Unit	1653
		Examiner Name	H. Robinson
		Attorney Docket Number	641050.90013 (12705.4)

RECEIVED
OCT 24 2002
TECH CENTER 1600/2900


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓		Mattern, Jurgen, et al., "Detection of Resistance Proteins in Matched Primary Lung Tumors and Lymph Node Metastases". Anticancer Research 14:417-420 (1994).	✓
		Drust, Debra S., et al., "Aggregation of chromaffin granules by calpactin at micromolar levels of calcium". Nature 331:88-91 (1988).	✓
		Lee, Jong Seok, et al., "Reduced Drug Accumulation and Multidrug Resistance in Human Breast Cancer Cells without Associated P-Glycoprotein or MRP Overexpression". Journal of Cellular Biochemistry 65:513-526 (1997).	✓
		Sehested, M., et al., "Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil". Br. J. Cancer 56:747-751 (1987).	✓
		Towbin, Harry, et al., "Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications". Proc. Natl. Acad. Sci. USA 76(9):4350-4354 (1979).	✓
		Tischler, David M., "Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of the central nervous system". J. Neurosurg. 76:507-512 (1992).	✓
		Creutz, Carl E., "The Annexins and Exocytosis". Science 258:924-931 (1992).	✓
		Chan, Helen S.L., "Multidrug resistance in pediatric malignancies". Hematology/Oncology Clinics of North America 9(2):275-319 (1995).	✓
		Yoshikazu Sugimoto, et al., "Molecular Cloning and Characterization of the Complementary DNA for the Mr 85,000 Protein Overexpressed in Adriamycin-resistant Human Tumor Cells ¹ ". Cancer Research 53:2538-2543 (1993).	✓
		Schinkel, Alfred H., et al., "Characterization of the Human MDR3 P-Glycoprotein and Its Recognition by P-Glycoprotein-specific Monoclonal Antibodies ¹ ". Cancer Research 51:2628-2635 (1991).	✓
		Kool, Marcel, et al., "Expression of Human MRP6, a Homologue of the Multidrug Resistance Protein Gene MRP1, in Tissues and Cancer Cells ¹ ". Cancer Research 59:175-182 (1999).	✓

Examiner Signature		Date Considered	1/14/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) in this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/529,925
				Filing Date	Julv 30. 2000
				First Named Inventor	Elias Georges
				Group Art Unit	1653
				Examiner Name	H. Robinson
				Attorney Docket Number	641050.90013 (12705.4)
Sheet	9	of	10		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
dk		Meers, Paul, et al., "Spermine as a Modulator of Membrane Fusion: Interactions with Acidic Phospholipids". Biochemistry 25:3109-3118 (1986).	/
		Wang, Wei, et al., "Regulation of the Chromaffin Granule Aggregating Activity of Annexin I by Phosphorylation". Biochemistry 31:9934-9939 (1992).	/
		Ausubel, Frederic, M., et al., "Current Protocols in Molecular Biology". Current Protocols in Molecular Biology 1:1-12 (1989).	/
		Campbell, Ailsa M., "Monoclonal antibody technology". Laboratory Techniques in Biochemistry and Molecular Biology 13:1 (1984).	/
		Kwoh, Deborah Y., et al., "Target amplification system in nucleic acid-based diagnostic approaches". Am. Biotechnol. Lab. 8:14-25 (1990).	/
		Morvan, Francois, et al., "DNA I. Synthesis, characterization by high field 1H-NMR, and base-pairing properties of the unnatural hexadeoxyribonucleotide . . ." Nucleic Acids Research 14(12):5019-5035 (1986).	/
		Osol, Arthur, et al., "Remington's Pharmaceutical Sciences". Philadelphia College of Pharmacy and Science, Jack Eds 16th (1980).	/
		Fogh, Jorgen, et al., "Human Tumor Cells In Vitro". Plenum Press, New York, pp. 155-159 (1975).	/
		Sambrook, et al., "Molecular Cloning". A Laboratory Manual, Second Edition pp. xi-xxxiii (1989).	/
		Ausubel, Fredrich M., et al., "Short Protocols in Molecular Biology". Current Protocols in Molecular Biology pp. iii-xvi (1989).	/
		Ecker, David J. and Griffey, Richard H., "RNA as a small-molecule drug target: doubling the value of genomics". DDT 4(9):420-429 (1999).	/

Examiner Signature		Date Considered	1/14/03
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/529,925
				Filing Date	July 30, 2000
				First Named Inventor	Elias Georges
				Group Art Unit	1653
				Examiner Name	H. Robinson
				Attorney Docket Number	641050.90013 (12705.4)
Sheet	10	of	10		

[illegible]

Examiner
Signature

Date _____

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.